Nation and world news briefs
Moderna delays Phase 3 trial for COVID-19 vaccineModerna’s heavily anticipated trial for a coronavirus vaccine, which was set to begin next week, has been delayed.“Moderna has previously disclosed that the Phase 3 trial of its COVID-19 vaccine candidate mRNA-1273 is expected to begin in July. The trial is still expected to begin in July and we expect to be the first to start a Phase 3 trial,” read a company statement sent to The New York Daily News Thursday. “We have worked closely with NIH/OWS to align on the final protocol in order to begin the trial on time.”The Phase 3 study, which include...
Tribune News Service
Moderna delays Phase 3 trial for COVID-19 vaccine
Moderna’s heavily anticipated trial for a coronavirus vaccine, which was set to begin next week, has been delayed.“Moderna has previously disclosed that the Phase 3 trial of its COVID-19 vaccine candidate mRNA-1273 is expected to begin in July. The trial is still expected to begin in July and we expect to be the first to start a Phase 3 trial,” read a company statement sent to The New York Daily News Thursday. “We have worked closely with NIH/OWS to align on the final protocol in order to begin the trial on time.”The Phase 3 study, which includes 30,000 patients, was initially supposed to begi...
New York Daily News
For some with COVID-19, symptoms can linger for weeks, even months
ATLANTA — When Nina Dalsania Makadia felt the first symptoms of COVID-19 in March, she braced herself for a couple of miserable weeks.The Kennesaw, Ga., mother of three young children expected the virus to be like a bad cold or the flu. Her headache, chills and fever would require rest and recuperation in bed, she thought. After that, she’d be better, and life would return to normal.But things haven’t returned to normal for the 38-year-old.Three months since falling ill, Makadia still can’t shake extreme exhaustion. Even going up and down the stairs in her home leaves her winded. Then there’s ...
The Atlanta Journal-Constitution
Commentary: On a doctor's right to try in the age of COVID-19
Should doctors who are working in COVID-19 intensive care units have access for themselves to Moderna’s potential coronavirus vaccine? U.S. health care workers are infected with the virus every day. If we have a probable vaccine that is almost certainly reasonably safe and likely to be effective, why shouldn’t doctors — who are scientifically trained to make these judgments — be allowed to vaccinate themselves to protect both their own lives and those they treat?Yes, it’s possible that there will be unacceptable side effects. Like other medicines, a COVID-19 vaccine may be right for some peopl...
Tribune News Service
San Diego biotech raises $90 million to treat infections in people with weak immune systems
SAN DIEGO — San Diego biotech company Amplyx Pharmaceuticals announced Tuesday that it has completed a $53 million extension to its Series C funding round, bringing the total for the round to $90 million.Sofinnova Venture Partners led the round, with participation from more than seven investment firms that had contributed in earlier rounds. Pfizer and Adage Capital Management joined the mix as new investors.The funds will mainly go toward testing two experimental drugs central to Amplyx’s mission — treating microbes that are usually harmless, but which can kill a person without a healthy immun...
The San Diego Union-Tribune
Stanford's new coronavirus treatment approach: Hit hard — and early
Research efforts are laser-focused on finding coronavirus treatments to save the most critically ill.But what about everyone else?A new clinical trial at Stanford University is part of an emerging movement to find COVID-19 medicines that can be given almost immediately after infection, before the virus gains a firm foothold in the body.If effective, this strategy could ease the misery of the estimated 80% of patients who experience mild or moderate symptoms. It might also reduce the risk of progression in the 20% of people at great risk of dangerous disease, and even slow viral spread.Hopes ar...
The Mercury News
Clinical trial enrollment plummets as volunteers are scared off coronavirus treatment pushed by Trump
SEATTLE — One of the hottest debates in the coronavirus pandemic is whether the malaria drugs promoted as possible treatments by President Donald Trump really work. But Americans don’t seem overly eager to help answer the question.Enrollment in several clinical trials of chloroquine and hydroxychloroquine — including two by the University of Washington — has been anemic so far. Fewer than 260 volunteers, out of a target of 2,000, have signed up for a $9.5 million UW study being conducted in Seattle and six other sites across the country. Another multi-site project coordinated by the UW has onl...
The Seattle Times
In a race against time, coronavirus vaccine testing expands
SAN JOSE, Calif. — In the battle to prevent COVID-19 infection, a vaccine will be our safest armor.As casualties climb, pharmaceutical companies and young volunteers are racing to design, build and test a defense that can protect us. Unless a vaccine is developed soon, people susceptible to the virus will continue to be at risk.Human testing has begun of six potential vaccines in an effort to prove that they’re safe and can produce an immune response. Over 70 more are being reviewed for safety and effectiveness in preparation for human testing. In promising news, this week Chinese researchers ...
The Mercury News
Northwestern testing drug to help treat a 'storm' inside the body caused by COVID-19
CHICAGO — Some patients with the novel coronavirus suffer a severe immune response that triggers potentially fatal hyperinflammation, studies have shown. The reaction, named for the body’s proteins that attack lung tissue, is known as a “cytokine storm.”“A storm is a good way to describe it,” Northwestern Medicine’s Dr. Richard Wunderink said. “It can cause acute respiratory distress syndrome, … essentially flooding the lungs.”In response, researchers like Wunderink are racing to see if they can find a way to prevent such a catastrophic chain of events. Northwestern Medicine in Chicago is test...
Experts hopeful but cautious about new coronavirus treatment report
ATLANTA — Cautious. Hopeful. Realistic.Those are words that medical experts are frequently using to describe results of a recent test of the drug remdesivir for patients hospitalized with severe infections of COVID-19.More than half of the patients were so ill that they were on mechanical ventilators, while another 8% were on a treatment that uses a pump to oxygenate blood outside the body.After receiving remdesivir once a day for up to 10 days, two-thirds of patients improved their support status, and nearly half were discharged from the hospital, researchers reported in an article published ...
The Atlanta Journal-Constitution